Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer (Q34309227)

1 August 2017

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer (English)

1 reference

1 August 2017

1 reference

Jeetendra Eswaraka

1

1 reference

1 August 2017

Anand Giddabasappa

2

1 reference

1 August 2017

Guangzhou Han

3

1 reference

1 August 2017

Kush Lalwani

4

1 reference

1 August 2017

Koleen Eisele

5

1 reference

1 August 2017

Zheng Feng

6

1 reference

1 August 2017

Timothy Affolter

7

1 reference

1 August 2017

James Christensen

8

1 reference

1 August 2017

Gang Li

9

1 reference

1 August 2017

language of work or name

English

0 references

publication date

2 October 2014

1 reference

1 August 2017

1 reference

1 August 2017

14

1 reference

1 August 2017

742

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-14-742

1 August 2017

0 references

cites work

Cancer statistics, 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Novel options for the treatment of castration-resistant prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Bone metastasis in prostate cancer: emerging therapeutic strategies.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Characterization of bone metastases from rapid autopsies of prostate cancer patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Pre-clinical mouse models of human prostate cancer and their utility in drug discovery

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Treatment and prevention of bone complications from prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

6 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Pathogenesis of osteoblastic bone metastases from prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Castration-resistant prostate cancer: locking up the molecular escape routes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

The cost of treating skeletal-related events in patients with prostate cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Clinical practice. Localized prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Skeletal implications of prostate cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Osteoblasts in prostate cancer metastasis to bone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Met, metastasis, motility and more

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

High expression of the Met receptor in prostate cancer metastasis to bone

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-14-742

Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-14-742

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-14-742

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4190397

Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer

28 October 2018

1 reference

12 December 2020

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer

1 reference

12 December 2020

Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts

1 reference

12 December 2020

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-14-742

1 reference

Dimensions Publication ID

1 August 2017

1020957346

0 references

Fatcat ID

release_hrgi7usxtzbr3efjuirv2bmbhe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hrgi7usxtzbr3efjuirv2bmbhe

24 November 2022

mapped directly with Wikidata item

PMCID

4190397

1 reference

1 August 2017

1 reference